Search alternatives:
marked decrease » marked increase (Expand Search)
marker decrease » larger decrease (Expand Search), marked increase (Expand Search), markedly decreased (Expand Search)
lasso decrease » largest decrease (Expand Search)
i marked » _ marked (Expand Search), _ market (Expand Search), _ marker (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
marked decrease » marked increase (Expand Search)
marker decrease » larger decrease (Expand Search), marked increase (Expand Search), markedly decreased (Expand Search)
lasso decrease » largest decrease (Expand Search)
i marked » _ marked (Expand Search), _ market (Expand Search), _ marker (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
-
1
-
2
-
3
-
4
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
5
-
6
-
7
-
8
-
9
-
10
-
11
Table 5_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
Published 2025“…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
-
12
Table 1_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
Published 2025“…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
-
13
Table 4_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
Published 2025“…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
-
14
Table 3_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
Published 2025“…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
-
15
Table 6_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
Published 2025“…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
-
16
Table 2_Immune-related diagnostic indicators and targeted therapies for COPD combined with NASH were identified and verified via WGCNA and LASSO.xlsx
Published 2025“…These findings suggest that S100A9 serves as a common inflammatory marker for both diseases, whereas MYH2 may be regulated by disease-specific mechanisms, highlighting its potential for distinguishing COPD from NAFLD.…”
-
17
-
18
-
19
-
20